News Article | February 27, 2017
Harwell Campus SWINDON, 27-Feb-2017 — /EuropaWire/ — A major new £100 million investment by the government into the development of an innovative multi-disciplinary science and technology research centre was announced today (Thursday 23 February 2017) by Business Secretary Greg Clark. The new Rosalind Franklin Institute (RFI) – named in honour of the pioneering British scientist whose use of X-rays to study biological structures played a crucial role in the discovery of DNA‘s ‘double helix’ structure by Francis Crick and James Watson – will bring together UK strengths in the physical sciences, engineering and life sciences to create a national centre of excellence in technology development and innovation. The new Rosalind Franklin Institute will have a hub based at the Harwell campus It will bring together UK expertise to develop new technologies that will transform our understanding of disease and speed up the development of new treatments Part of the government’s Industrial Strategy to maintain the UK’s global leadership in science, innovation and research Business Secretary Greg Clark said: The UK has always been a pioneer in the world of science, technology and medical research. It’s this excellence we want to continue to build on and why we made science and research a central part of our Industrial Strategy – strengthening links between research and industry, ensuring more home-grown innovation continues to benefit millions around the world. Named after one of the UK’s leading chemists, the new Rosalind Franklin Institute will inspire and house scientists who could be responsible for the next great discovery that will maintain the UK’s position at the forefront of global science for years to come. Delivered and managed by the Engineering and Physical Sciences Research Council (EPSRC), the RFI will bring together academic and industry researchers from across the UK to develop disruptive new technologies designed to tackle major challenges in health and life sciences, accelerate the discovery of new treatments for chronic diseases affecting millions of people around the world (such as dementia), and deliver new jobs and long-term growth to the local and UK economies. Chair of the Research Councils and EPSRC Chief Executive, Professor Philip Nelson said: The UK is currently in a world leading position when it comes to developing new medical treatments and technologies in the life sciences. However, other countries are alive to the potential and are already investing heavily. The Rosalind Franklin Institute will help secure the country as one of the best places in the world to research, discover, and innovate. The central hub at Harwell will link to partner sites at the universities of Cambridge, Edinburgh, Manchester and Oxford, Imperial College, King’s College London, and University College London. Industry partners will be on board from the outset, and the Institute will grow over time, as more universities and researchers participate. The work at new Institute will contribute directly to the delivery of EPSRC‘s ‘Healthy Nation’ prosperity outcome, its Healthcare Technologies programme, and to the Technology Touching Life initiative that spans three research councils (the Biotechnology and Biological Sciences Research Council (BBSRC), the Medical Research Council (MRC) and EPSRC) and seeks to foster interdisciplinary technology development research across the engineering, physical and life sciences. The development of the RFI has been led by Professor Ian Walmsley, FRS, from the University of Oxford, who said: This is a new joint venture between some of the UK’s leading universities and key partners in industry and research councils. The aim is to speed the application of cutting-edge physical science insights, methods and techniques to health and life sciences by providing an interface between research programmes at the forefront of these areas, co-located at Harwell and connected, dynamically, to the wider UK research base. We anticipate innovative new businesses will grow from this effort over time, as the Institute will engage with a range of key industries from inception. A collaborative joint venture model allows the RFI to make the most of interactions and draw on a wide range of existing research excellence from across the UK. Patrick Vallance, President of R&D at GSK said: We welcome the creation of the RFI which will bring world-leading, multi-disciplinary teams from industry and academia closer together, and will further strengthen the UK as a place to translate excellent science into patient benefit. Through collaboration we will be able to make advances in life science technologies much quicker than we could manage alone. Research at the RFI will initially be centred on five selected technology themes, focusing on next-generation imaging technologies – X-ray science, correlated imaging (combining X-ray, electron and light microscopy), imaging by sound and light, and biological mass spectrometry – and on new chemical methods and strategies for drug discovery. Dame Carol Robinson, FRS, who is leading the RFI‘s biological mass spectrometry theme, and received the 2004 Royal Society Rosalind Franklin Award that recognises outstanding scientific contributions and supports the promotion of women in science, technology, engineering and mathematics, said: It is fitting that this new Institute bears Rosalind Franklin’s name. She achieved so much in a relatively short life and without her work many of the advances that have taken place since would not have come about. Work in the Institute will include development of the next-generation of physical tools including mass spectrometry, instruments for X-ray science and for advanced microscopy – fields directly descended from her research interests. Notes for Editors: The Engineering and Physical Sciences Research Council (EPSRC) As the main funding agency for engineering and physical sciences research, our vision is for the UK to be the best place in the world to Research, Discover and Innovate. By investing £800 million a year in research and postgraduate training, we are building the knowledge and skills base needed to address the scientific and technological challenges facing the nation. Our portfolio covers a vast range of fields from healthcare technologies to structural engineering, manufacturing to mathematics, advanced materials to chemistry. The research we fund has impact across all sectors. It provides a platform for future economic development in the UK and improvements for everyone’s health, lifestyle and culture. We work collectively with our partners and other Research Councils on issues of common concern via Research Councils UK. The Science and Technology Facilities Council (STFC) STFC is keeping the UK at the forefront of international science and tackling some of the most significant challenges facing society such as meeting our future energy needs, monitoring and understanding climate change, and global security. The Council has a broad science portfolio and works with the academic and industrial communities to share its expertise in materials science, space and ground-based astronomy technologies, laser science, microelectronics, wafer scale manufacturing, particle and nuclear physics, alternative energy production, radio communications and radar. STFC operates or hosts world class experimental facilities including in the UK the ISIS pulsed neutron source, the Central Laser Facility, and LOFAR, and is also the majority shareholder in Diamond Light Source Ltd. It enables UK researchers to access leading international science facilities by funding membership of international bodies including European Laboratory for Particle Physics (CERN), the Institut Laue Langevin (ILL), European Synchrotron Radiation Facility (ESRF) and the European Southern Observatory (ESO). STFC is one of seven publicly-funded research councils. It is an independent, non-departmental public body of the Department for Business, Energy and Industrial Strategy (BEIS). The Biotechnology and Biological Sciences Research Council (BBSRC) BBSRC invests in world-class bioscience research and training on behalf of the UK public. Our aim is to further scientific knowledge, to promote economic growth, wealth and job creation and to improve quality of life in the UK and beyond. Funded by Government, BBSRC invested £473M in world-class bioscience, people and research infrastructure in 2015-16. We support research and training in universities and strategically funded institutes. BBSRC research and the people we fund are helping society to meet major challenges, including food security, green energy and healthier, longer lives. Our investments underpin important UK economic sectors, such as farming, food, industrial biotechnology and pharmaceuticals. More information about BBSRC strategically funded institutes. The Medical Research Council (MRC) The Medical Research Council is at the forefront of scientific discovery to improve human health. Founded in 1913 to tackle tuberculosis, the MRC now invests taxpayers’ money in some of the best medical research in the world across every area of health. Thirty-one MRC-funded researchers have won Nobel prizes in a wide range of disciplines, and MRC scientists have been behind such diverse discoveries as vitamins, the structure of DNA and the link between smoking and cancer, as well as achievements such as pioneering the use of randomised controlled trials, the invention of MRI scanning, and the development of a group of antibodies used in the making of some of the most successful drugs ever developed. Today, MRC-funded scientists tackle some of the greatest health problems facing humanity in the 21st century, from the rising tide of chronic diseases associated with ageing to the threats posed by rapidly mutating micro-organisms. www.mrc.ac.uk Diamond Light Source Diamond Light Source is the UK’s synchrotron science facility, and is approximately the size of Wembley Stadium. It works like a giant microscope, harnessing the power of electrons to produce bright light that scientists can use to study anything from fossils to jet engines to viruses and vaccines. Diamond is used by thousands of academic and industrial researchers across a wide range of disciplines, including structural biology, health and medicine, solid-state physics, materials & magnetism, nanoscience, electronics, earth & environmental sciences, chemistry, cultural heritage, energy and engineering. Many everyday commodities that we take for granted, from food manufacturing to consumer products, from revolutionary drugs to surgical tools, from computers to mobile phones, have all been developed or improved using synchrotron light. Diamond generates extremely intense pin-point beams of synchrotron light. These are of exceptional quality, and range from X-rays to ultraviolet to infrared. Diamond’s X-rays are around 10 billion times brighter than the sun. Diamond is one of the most advanced scientific facilities in the world, and its pioneering capabilities are helping to keep the UK at the forefront of scientific research. 2017 marks a double celebration for Diamond – 15 years since the company was formed, and 10 years of research and innovation. In this time, researchers who have obtained their data at Diamond have authored over 5,000 papers. The institute is funded by the UK Government through the Science and Technology Facilities Council (STFC), and by the Wellcome Trust The Harwell Campus Harwell Campus is a public private partnership between Harwell Oxford Partners, U+I Group PLC and two Government backed agencies, the Science and Technology Facilities Council (STFC) and the UK Atomic Energy Agency (UKAEA). Harwell is one of the world’s most important science and innovation locations. It has a growing reputation as the UK’s gateway to space with over 65 space and satellite applications related organisations located on campus and is now seeing rapid growth in the Life Sciences and HealthTec sector with over 1,000 people working in this field alone at Harwell. In addition to space and life sciences, the campus hosts an array of other key sectors including, Big Data and Supercomputing, Energy and Environment and Advanced Engineering and Materials. With a legacy of many world firsts, the campus comprises 710 acres, over 200 organisations and 5,500 people. Harwell Campus is the UK’s National Science Facility and is among Europe and the world’s leading sites dedicated to the advancement of science, technology and innovation. Having spent 75 years at the forefront of British innovation and discovery, Harwell Campus continues to drive scientific advancements to the benefit of the UK economy and centred around a community hub. Science experts, academics, government organisations, private sector R&D departments and investors create an environment where innovation, collaboration and discovery thrive. Harwell’s Cluster Strategy The Cluster of about 70 Space organisations at Harwell is testament to the power of co-locating industry, academia and the public sector alongside investors and entrepreneurs. The European Space Agency, RAL Space, The UK Space Agency, Airbus, Thales Alenia Space, Lockheed Martin, and Deimos Space UK can all be found on the Campus. This creates many opportunities for collaboration, increasing capability and sharing risk. Being within a Cluster brings access to high-quality common infrastructure, facilities and expertise, alongside exposure to new markets The Harwell vision is to be home to a number of Clusters that exploit the existing strengths of the Campus. The next step is a new HealthTec Cluster that will benefit from the considerable synergies across the life and physical sciences capabilities of the Campus and the Space cluster. These clusters will enrich each other, creating a powerful multidisciplinary environment tailored to problem solving that will allow the UK to compete with the best in the world. The clustering of industries, facilities and science experts has given rise to the term Harwell Effect – and is an ideal model for future science and business innovation programmes. Science clusters drive economic growth. MIT has created businesses with a combined value of $3tn, the equivalent of California’s GDP. Harwell Campus is the only location in the UK with the potential to emulate this success. To find out more about events, open days or the new developments, visit the Harwell Campus website. SOURCE: EPSRC Contact Details In the following table, contact information relevant to the page. The first column is for visual reference only. Data is in the right column. Name: EPSRC Press Office Telephone: 01793 444404
News Article | March 2, 2017
CAMBRIDGE, Mass. & CAMBRIDGE, England--(BUSINESS WIRE)--Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (BicycleTM) product platform, announced today that Kevin Lee, Ph.D., Bicycle’s Chief Executive Officer, will present a company overview at the Cowen and Company 37th Annual Health Care Conference in Boston, MA. The presentation will take place at 8:30 a.m. ET on Tuesday, March 7, 2017 in the MIT Room at the Boston Marriott Copley Place. About Bicycle Therapeutics Bicycle Therapeutics is developing a new class of medicines to treat oncology and other debilitating diseases based on its proprietary bicyclic peptide (BicycleTM) product platform. BicyclesTM exhibit an affinity and exquisite target specificity usually associated with antibodies, while a low molecular weight delivers rapid and deep tissue penetration enabling more efficient tumor targeting. Their peptidic nature provides a “tuneable” pharmacokinetic half-life and a renal route of clearance, avoiding the liver and gastrointestinal tract toxicities often seen with other drug modalities. Bicycle Therapeutics is rapidly advancing towards the clinic with its lead molecule, BT1718, and is collaborating in oncology and other areas to realize the full potential of the technology. Bicycle Therapeutics’ unique intellectual property is based on the work initiated at the MRC Laboratory of Molecular Biology in Cambridge, U.K., by the scientific founders of the company, Sir Gregory Winter and Professor Christian Heinis. Bicycle Therapeutics is headquartered in Cambridge, U.K., with a U.S. subsidiary in Cambridge, Massachusetts. For more information, visit www.bicycletherapeutics.com.
News Article | February 21, 2017
Wiseguyreports.Com Adds “Subsea Production And Processing System -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2022” To Its Research Database According to Stratistics MRC, the Global Subsea Production and Processing System market is expected to grow from $16.76 billion in 2015 to reach $26.69 billion by 2022 with a CAGR of 6.9%. Growing new oil discoveries as well growing number of offshore drilling activities in subsea areas of emerging economies is influencing the market growth. In addition, raising emphasis on deep water drilling, and huge hydrocarbon reserves are propelling the market growth, over the forecast period. On the other hand, instability in crude oil and gas prices brought together with political, technological and operational risks are anticipated to hinder the market. Europe commands the markets in terms of market size, during the forecast period. Asia Pacific is expected to witness high growth rate during the forecast period. It is attributed to improved exploration activity into deep water areas and smooth government regulations towards offshore exploration. By subsea production technologies, the subsea umbilicals risers flowlines (SURF) segment leads the market globally with the biggest market share and is expected to grow with a high CAGR during the forecast period. Some of the key players in global subsea production and processing system market include ABB Ltd., Aker Solutions, Dril-Quip Inc., FMC Technologies, GE Oil & Gas, Kongsberg, National Oilwell Varco, Nexans SA, Oceaneering International, Inc., Onesubsea, Parker Hannifin Corporation, Siemens AG, Technip, Twister BV, and Vallourec. Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK o Spain o Rest of Europe • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements For more information, please visit https://www.wiseguyreports.com/sample-request/674304-subsea-production-and-processing-system-global-market-outlook-2016-2022
News Article | March 2, 2017
Une étude multicentrique va commencer aux États-Unis et en Europe au quatrième trimestre 2017 ST. LOUIS, 2 mars 2017 /PRNewswire/ -- MediBeacon Inc, une société de portefeuille intégrée à la plateforme Pansend Life Sciences de HC2 Holdings, Inc. (NYSE MKT : HCHC), a annoncé aujourd'hui la clôture réussie d'une étude clinique portant sur des patients souffrant d'insuffisance rénale. L'étude été menée en temps réel au service d'hématologie de l'Université Washington à St. Louis. Au cours de l'étude clinique, on a évalué la fonction rénale de patients affichant toute la gamme des insuffisances : depuis le débit normal jusqu'à l'insuffisance rénale chronique sévère (MRC de stade 4). L'étude comprenait également des patients de l'hôpital universitaire de Saint-Louis. Pour évaluer le taux de filtration glomérulaire (« GFR »), MediBeacon a recours à un capteur optique cutané associé à un agent breveté qui brille en présence de lumière. Le système a été conçu pour fournir aux cliniciens une surveillance continue en temps réel de la fonction rénale sans nécessiter de prise de sang. « La conclusion de notre étude clinique sur des patients souffrant d'insuffisance rénale représente une étape importante », a déclaré Steve Hanley, PDG de MediBeacon. « Nous prévoyons commencer notre étude clinique multicentrique dans des centres situés aux États-Unis et en Europe au cours du quatrième trimestre 2017 ». Les échantillons sanguins prélevés dans la pratique clinique actuelle fournissent des estimations différées et souffrent d'une variabilité qui peut conduire à des inexactitudes. « Les méthodes d'évaluation de la fonction rénale n'ont pas changé en 25 ans », a ajouté le Dr Richard Solomon, « Patrick Professor of medecine » et directeur, Division de néphrologie et d'hypertension artérielle à l'École de médecine de l'Université du Vermont. « Le système de thérapie ponctuelle de MediBeacon pourrait représenter une percée majeure pour évaluer la fonction rénale ». « Les progrès que MediBeacon continue à faire dans la validation de leur technologie nous enthousiasment au plus haut point », a ajouté Philip Falcone, PDG et chef de la direction de HC2. « À terme, les innovations de MediBeacon offrent le potentiel d'améliorer les soins thérapeutiques et de réduire les coûts du système de soins de santé ». Des applications technologiques de MediBeacon sont en cours d'évaluation dans les domaines des soins rénaux, de la perméabilité gastro-intestinale et de l'angiographie optique. Le portefeuille de propriété intellectuelle (PI) de la société compte 29 brevets américains accordés, et 17 demandes de brevet. En septembre 2016, MediBeacon a reçu une subvention du National Eye Institute (NEI), une institution membre des National Institutes of Health (NIH). La subvention porte le numéro R43EY027207. Grâce à ce soutien, la Société poursuit des recherches sur l'utilisation d'un agent fluorescent traceur MediBeacon pour visualiser la vascularisation oculaire. En octobre 2016, en collaboration avec l'Université Washington, MediBeacon a reçu, de la Fondation Bill & Melinda Gates, une subvention de 1,1 million USD pour un projet de recherche visant à mieux analyser la malnutrition infantile et ses problèmes connexes, y compris le retard de croissance. La mission de MediBeacon est de commercialiser des agents de diagnostic optiques biocompatibles pour la surveillance physiologique, le guidage chirurgical, et l'imagerie des pathologies dans la population humaine. La propriété intellectuelle de MediBeacon contient plusieurs concepts de produits conçus pour ces domaines. Le portefeuille de MediBeacon comprend un système d'évaluation de la fonction rénale qui utilise un capteur optique cutané associé à un traceur fluorescent exclusif qui brille en présence de lumière. Actuellement en cours d'évaluation chez l'être humain, ce système est conçu pour fournir aux cliniciens une surveillance continue en temps réel de la fonction rénale d'un patient. Vous en saurez plus sur MediBeacon en consultant le site www.medibeacon.com HC2 Holdings, Inc. (NYSE : HCHC), une société de portefeuille diversifiée, cotée en bourse, cherche à acquérir et à développer des entreprises attrayantes susceptibles de générer à terme des flux de trésorerie disponibles et d'offrir un rendement maximal à toutes les parties prenantes. HC2 gère un large éventail de filiales en exploitation dans de très nombreux secteurs, dont les suivants : fabrication, services maritimes, services publics, télécommunications, sciences de la vie, assurances et autres. Parmi les principales filiales d'exploitation de HC2, figurent DBM Global Inc., un groupe de sociétés fournissant des services entièrement intégrés de constructions en acier et structurelles, et Global Marine Systems Limited, un fournisseur leader de services d'ingénierie et de maintenance pour câbles sous-marins. Fondée en 1994, HC2 a établi son siège social à New York, New York. Vous en saurez plus sur HC2 et ses sociétés de portefeuille en consultant le site www.hc2.com
News Article | February 21, 2017
GRAND RAPIDS, Mich. (Feb. 21, 2017)--An international collaboration of life scientists, including experts at Van Andel Research Institute, has described in exquisite detail the critical first steps of DNA replication, which allows cells to divide and most advanced life, including human, to propagate. Results of the study are published in the journal Nature Structural and Molecular Biology and reveal that a ring-shaped protein called origin recognition complex (ORC) possesses a special alpha-helix, which slips into a groove on DNA and initiates a cascade of microscopic interactions that copy DNA. "This is a story of one ring that lords over another ring," says Huilin Li, Ph.D., a professor in Van Andel Research Institute's Center for Epigenetics and a senior author of the paper. "Biologists have known for many years that both ORC and helicase are ring-shaped structures essential in the initiation and execution of DNA replication, but until now we never understood exactly how the ORC ring loads the helicase ring onto DNA." The work also reveals that ORC, with the help of Cdc6 and Cdt1, loads the helicase core onto DNA via paired interactions of the so-called winged helix domains. The resulting 14-protein structure completes the loading of the first helicase ring and is now prepared to load the next ring. This process represents the inception of an immensely complex and elegant system that is constantly ongoing at tens of thousands of points on the DNA in many cells of the human body, and it all starts with ORCs. "We hope that by mapping this process, others will eventually convert this knowledge into new treatments for DNA replication-related conditions, including many cancers and rare disorders," says Li. At the outset, the six-protein ORCs assemble into a crescent, which envelops the DNA duplex. The ORCs then recruit a seventh protein, called Cdc6, to encircle DNA. Next, this ring threads the second ring, called minichromosome maintenance protein (Cdt1-bound Mcm2-7 hexamer), around DNA, which completes loading of the first Mcm2-7 hexamer. "It's like threading a pearl onto a string; but unlike a short piece of string, the DNA strand is incredibly long and so the bead cannot be threaded on at one end," says Christian Speck, a professor at Imperial College of London's Institute of Clinical Sciences, leader of the DNA Replication group at MRC London Institute of Medical Sciences and a senior author of the paper. "Instead, it must somehow be opened up, slotted around the strand, and closed again." The study was conducted on the DNA of Saccharomyces cerevisiae, better known as baker's yeast, because of its biological and genomic similarity to larger organisms, including mammals, at an average resolution of 3.9 Angströms (about 40 billionths of a meter), which is roughly the diameter of a single atom of sodium. Magnification of this scale is currently possible only with cryoelectron microscopy (cryo-EM), a revolutionary technology VARI continues to invest in through its recently established Cryo-EM Core. Imaging for this study was conducted at Howard Hughes Medical Institute's Janelia Research Campus and at Scripps Research Institute. Study authors are Zuanning Yuan, Lin Bai, Jingchuan Sun and Huilin Li, of Van Andel Research Institute; Alberto Riera, Marta Barbon and Christian Speck, all of Imperial College of London and MRC London Institute of Medical Sciences; Jingchuan Sun of University of Pennsylvania; Saikat Nandi and Bruce Stillman, both of Cold Spring Harbor Laboratory; Christos Spanos, Zhuo Angel Chen and Juri Rappsilber, all of University of Edinburgh. Rappsilber is also affiliated with Technische Universität Berlin. Sun is now affiliated with University of Pennsylvania. This work was funded by the U.S. National Institutes of Health (GM111472 and OD12272 to Huilin Li and GM45436 to Bruce Stillman), the Biotechnology and Biological Sciences Research Council UK (P56061 to Christian Speck), and the Wellcome Trust (Investigator Award P56628 to Speck, Senior Research Fellowship 103139 to Juri Rappsilber, a Centre core grant 092076 to Rappsilber, and an instrument grant 108504 to Rappsilber). Van Andel Institute (VAI) is an independent nonprofit biomedical research and science education organization committed to improving the health and enhancing the lives of current and future generations. Established by Jay and Betty Van Andel in 1996 in Grand Rapids, Michigan, VAI has grown into a premier research and educational institution that supports the work of more than 360 scientists, educators and staff. Van Andel Research Institute (VARI), VAI's research division, is dedicated to determining the epigenetic, genetic, molecular and cellular origins of cancer, Parkinson's and other diseases and translating those findings into effective therapies. The Institute's scientists work in onsite laboratories and participate in collaborative partnerships that span the globe. Learn more about Van Andel Institute or donate by visiting http://www. .
News Article | February 27, 2017
Wiseguyreports.Com Adds “Mobile Mapping -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2022” To Its Research Database According to Stratistics MRC, the Global Mobile Mapping market is estimated to be $10.28 billion in 2015 and is expected to reach $39.8 billion by 2022 growing at a CAGR of 21.3% from 2015-2022. Growing usage of mobile devices, enhanced network connectivity and rising growth for mapping analytics are some of the predominant growth drivers for the market. However, lack of awareness based on location-based services (LBS) is presumed to challenge the industry growth. Moreover, the future opportunity for the market lies in mobile mapping incorporation with wearable smart devices. Transportation and logistics segment is the largest revenue contributor to the market attributed to growing developments in monitor mobile resources. Furthermore, North America commanded the largest market share and dominated the global market due to more number of utilizing mapping applications and location based services (LBS). Some of the key players in this market include Apple, Inc., Leica Geosystems AG, NavInfo, ArcGIS Online (Esri), Baidu Maps, Ericsson, Foursquare Labs, Inc, GeoMapServer and Inrix Industry Covered: • Banking and finance • Government and Public Sector • Manufacturing • Retail • Media and Entertainment • Travel and Hospitality • Telecommunication • Transportation and Logistics • Oil and Gas • Military • Mining Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK o Spain o Rest of Europe • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements Contact Info: Name: NORAH TRENT Email: email@example.com Organization: WiseGuy Research Consultant Pvt Ltd Address: WISE GUY RESEARCH CONSULTANTS PVT LTD Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar Pune - 411028 Maharashtra, India Ph: +91 841 198 5042 firstname.lastname@example.org Phone: +1-646-845-9349 (US) +44 208 133 9349 (UK) For more information, please visit https://www.wiseguyreports.com/sample-request/674327-mobile-mapping-global-market-outlook-2016-2022
News Article | March 3, 2017
“According to Stratistics MRC, the Global Narrowband IoT Chipset Market is accounted for $6.95 million in 2015 and is expected to reach $180.25 million by 2022 growing at a CAGR of 59.2% during the forecast period”. Factors such as demand for long-range connectivity, growing demand for cellular IoT networks and lower component costs are propelling the market growth. Lack of standardization and privacy and security concerns are hampering the market growth. Increase in internet penetration and rising performance of narrowband IoT technology are providing ample of opportunities for the market growth. By application, infrastructure segment is expected to hold the largest market share during the forecast period. By deployment type, guard band segment is anticipated to command the largest market share and standalone segment is expected to grow at the highest CAGR during the forecast period. North America holds the major market share in the global narrowband IoT chipset market. Asia Pacific is expected to witness the highest growth during the forecast period. Rising internet penetration along with government support for enhancing the IoT technology has been some of the major reasons fueling the growth of narrowband IoT technology in Asia Pacific. Some of the key players in Narrowband IoT Chipset market include Nokia Corporation, Qualcomm Incorporated, Huawei Technologies Co. Ltd., Mistbase Communication System, Commsolid GmbH, Verizon Communications, Vodafone Group PLC, U-Blox Holding AG, Intel Corporation, Ericsson, Sequans Communications S.A. and Samsung Electronics. Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK o Spain o Rest of Europe • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements 4 Porters Five Force Analysis 4.1 Bargaining power of suppliers 4.2 Bargaining power of buyers 4.3 Threat of substitutes 4.4 Threat of new entrants 4.5 Competitive rivalry Gaining an insight into emerging trends, opportunities and potential threats is key to long-term sustenance in a competitive environment. The handpicked collection of market research reports on Wise Guy Reports is centred on this proven principle. Wise Guy Reports seasoned and well-informed team of Research Coordinators will work closely with you, offering unbiased and expert advice on the most appropriate market research reports. With their in-depth knowledge of market research trends, industry verticals and market research publishers, many organizations regard the services of our Research Coordinators as being indispensable. These services are also geared towards helping organizations obtain market research reports at the best price. For more information, please visit https://www.wiseguyreports.com/sample-request/827015-narrowband-iot-chipset-global-market-outlook-2016-2022
News Article | February 17, 2017
Recognised for Continued Commitment to Quality and Transparent Measurement Solutions in the Digital Advertising Market Blasting News, one of the largest global social news publishers, today announced that they have selected comScore validated Campaign Essentials™ (vCE®) to identify and remove fraudulent traffic in order to give Blasting News clients increased confidence that their ads have the opportunity to make an impact with a real and validated audience. The invalid traffic plague is a serious issue on the web. According to a 2015 report by the IAB invalid traffic caused advertisers to lose no less than $4.2 billion each year. Blasting News has integrated since its inception anti-bot technologies across its audience measurement systems, in order to create a safe place for brands and advertisers. However, invalid traffic generators are getting more sophisticated by the day, which is one of the reasons comScore has been selected to track reader flows and filter any invalid traffic activity on the Blasting News website. In November 2016, comScore was granted accreditation by the Media Rating Council (MRC) for Sophisticated Invalid Traffic (SIVT*) detection and filtration of desktop and mobile web traffic. comScore is the first company to offer both content and campaign measurement leveraging MRC-accredited SIVT filtration, providing the market with consistent and filtered metrics for the planning, buying, selling, and evaluation of digital advertising. "If advertising isn't reaching a real person, that's a real problem. We want to have 100% real human traffic, with no compromise. From now on, comScore will measure all Blasting News traffic and provide actionable data to help us take immediate action. That means that advertisers can be confident that they are only paying for human audiences on their campaigns, thanks to the metrics comScore provides" said Andrea Manfredi, CEO of Blasting News. Timur Yarnall, SVP Advertising, comScore, added: "Sophisticated IVT (SIVT) detection is extremely important due to how complex and fast-changing fraud techniques have become. comScore is committed to help our clients defend their business against these advanced techniques of malpractice and provide a safe, high quality environment for digital advertising." To learn more about comScore vCE, please visit http://www.comscore.com/Products/Advertising-Analytics/validated-Campaign-Essentials-2 or contact us. * The MRC's definition of Sophisticated IVT includes "traffic identified through advanced analytics, multipoint corroboration, human intervention-such as hijacked devices, ad tags, or creative; adware; malware; misappropriated content." Blasting News is the largest global social news publisher - set up in mid-2013, it is now the 142nd most visited websites in the world, thanks to 100+ million monthly unique on-site visitors. Blasting News has readers in five continents, offices in London, New York, Sao Paulo, Milan, Rome, and soon Singapore and a brand new US Edition - Blasting News US - recently launched. Blasting News is a new disruptive concept of journalism, being made by the people, for the people. News is produced by delocalized freelance contributors (Blasters), fact-checked and curated by a quality team of senior professionals. Furthermore, news is distributed by Social Blasters, a global team of top digital influencers. All the processes are fuelled by the crowd, without any central newsroom - thanks to an extensive use of technology (the core stages are managed by algorithms, some of which are patent-pending). comScore is a leading cross-platform measurement company that precisely measures audiences, brands and consumer behavior everywhere. comScore completed its merger with Rentrak Corporation in January 2016, to create the new model for a dynamic, cross-platform world. Built on precision and innovation, our unmatched data footprint combines proprietary digital, TV and movie intelligence with vast demographic details to quantify consumers' multiscreen behavior at massive scale. This approach helps media companies monetize their complete audiences and allows marketers to reach these audiences more effectively. With more than 3,200 clients and global footprint in more than 75 countries, comScore is delivering the future of measurement. Shares of comScore stock are currently traded on the OTC Market (OTC:SCOR). For more information on comScore, please visit comscore.com. To get in touch with Blasting News team, please write to: email@example.com
News Article | February 17, 2017
According to Stratistics MRC, the global smart motors market is accounted for $1.03 billion in 2015 and is expected to reach $1.69 billion by 2022 growing at a CAGR of 7.21% from 2015 to 2022.
News Article | February 21, 2017
According to Stratistics MRC, the global 3D Printing Gases market is accounted for $24.65 million in 2015 and is expected to reach $57.46 million by 2022 growing at a CAGR of 12.85% from 2015 to 2022.